Abstract LB-216: NCI 9455: Phase II study of trametinib followed by trametinib plus AKT inhibitor,GSK2141795 in patients with advanced triple negative breast cancer
Year: 2016
Type: conference-abstract
Source: Cancer Research
Authors: Bhuvaneswari Ramaswamy, Ewa Mrozek, Maryam Lustberg, Robert Wesolowski, Rachel Layman, Mahmoud Abdel-Rasoul, Cynthia Timmers, Robyn Patrick, Jennifer Sexton, Erin Macrae, Charles Shapiro, Thomas Budd, Lyndsay Harris, Claudine Isaacs, Roohi Ismail-Khan, Claire Dees, Andrew Poklepovic, Micheal Grever, Helen Chen, Miguel Villalona, William Carson
Institutions: The Ohio State University, Columbus Oncology and Hematology Associates, Tisch Cancer Institute, Cleveland Clinic, University Hospitals of Cleveland, Georgetown Lombardi Comprehensive Cancer Center, Moffitt Cancer Center, UNC Lineberger Comprehensive Cancer Center, Virginia Commonwealth University, National Cancer Institute
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2504781244